Oxford, the Mecca for blood coagulation research in the 1950s and 1960s
Prophylaxis for travel-related thrombosis? Yes
Prophylaxis for travel-related thrombosis? No
Platelets at a crossroad of pathogenic pathways in sepsis
Platelet function in sepsis
Does hypercoagulability awaken dormant tumor cells in the host?
Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway
Vitamin K
The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis
Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia
Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans
The influence of venous thromboembolism on quality of life and severity of chronic venous disease
High risk of recurrent venous thromboembolism in men
Risk factors for venous thrombosis in medical inpatients
Inhibition and reversal of platelet-rich arterial thrombus in vivo
Latent antithrombin and its detection, formation and turnover in the circulation
Lupus anticoagulant testing using plasma spiked with monoclonal antibodies
Tissue factor haploinsufficiency during endotoxin induced coagulation and inflammation in mice
Fibrinogen Mannheim II
The profibrinolytic effect of plasma thrombomodulin in factor XI deficiency and its implications in hemostasis
Interleukin-6-induced plasminogen gene expression in murine hepatocytes is mediated by transcription factor CCAAT/enhancer binding protein β (C/EBPβ)
The roles of ADP and TXA2 in botrocetin/VWF-induced aggregation of washed platelets
Activation of the small GTPase Rap2B in agonist-stimulated human platelets
Probing platelet factor 4 α-granule targeting
Tissue factor pathway inhibitor revisited
Tissue factor pathway inhibitor revisited
Tissue factor pathway inhibitor revisited
Tissue factor pathway inhibitor revisited
Tissue factor pathway inhibitor revisited
Tissue factor pathway inhibitor revisited
The multiple faces of the partial thromboplastin time APTT
The multiple faces of the partial thromboplastin time APTT
The multiple faces of the partial thromboplastin time APTT
The multiple faces of the partial thromboplastin time APTT
The multiple faces of the partial thromboplastin time APTT
The multiple faces of the partial thromboplastin time APTT
Diagnosing deep vein thrombosis
Is the current classification of venous thromboembolism acceptable? No
Effect of factor VII −323 Del/Ins polymorphism on the daily variability of factor VIIc and INR in steady anticoagulated patients with acenocoumarol
Production of plasminogen activator inhibitor-1 (PAI-1) by endothelial cells
Evaluation of denaturing high-performance liquid chromatography (DHPLC) in the screening of mutations in hemophilia B patients
Improvement of statin-associated myotoxicity by L-carnitine
First identification and expression of a type 2N von Willebrand disease mutation (E1078K) located in exon 25 of von Willebrand factor gene
Successful management of intramural ureteral hemorrhage in a patient with factor VIII deficiency and high-titer inhibitor
Enhanced factor VIII activity measurements using ROTEG and factor VIII–/– mice whole blood
More on
Time lag in platelet function inhibition by clopidogrel in stroke patients as measured by PFA-100
Template bleeding time and PFA-100® have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages
Template bleeding time and PFA-100® have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages
Template bleeding time and PFA-100® have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages
TALKING ABOUT…
Announcements